Not yet recruitingPhase 2NCT05518994

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Henan Provincial People's Hospital
Principal Investigator
Xingyao Bu
Henan Provincial People's Hospital
Intervention
Tislelizumab plus Bevacizumab(drug)
Enrollment
70 target
Eligibility
18 years · All sexes
Timeline
20222027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05518994 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials